- Quarterly Report (10-Q)

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2008

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to _________________

Commission File Number: 001-33966

MAKO Surgical Corp.

(Exact name of registrant as specified in its charter)

Delaware	20-1901148
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

2555 Davie Road, Fort Lauderdale, Florida 33317

(Address of Principal Executive Offices) (Zip Code)

(954) 927-2044

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer o

Accelerated Filer o

Non-accelerated Filer x

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

Number of shares outstanding of each of the issuer’s classes of common stock as of October 31, 2008:

Class		Outstanding at October 31, 2008
Common Stock		24,930,943

MAKO Surgical Corp.

INDEX TO FORM 10-Q

		Page No.
	Part I – Financial Information

Item 1	Financial Statements (unaudited)	1
	Condensed balance sheets at September 30, 2008 and December 31, 2007	1
	Condensed statements of operations for the three and nine months ended September 30, 2008 and 2007	2
	Condensed statements of cash flows for the nine months ended September 30, 2008 and 2007	3
	Notes to condensed financial statements	4
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3	Quantitative and Qualitative Disclosures about Market Risk	25
Item 4T	Controls and Procedures	26

	Part II – Other Information

Item 1	Legal Proceedings	27
Item 1A	Risk Factors	27
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 6	Exhibits	28

Signatures		28

Exhibit Index		29
Exhibit 31.1
Exhibit 31.2
Exhibit 32.1
Exhibit 32.2

Table of Contents

PART I

FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS .

MAKO SURGICAL CORP.

Condensed Balance Sheets

(in thousands, except share and per share data)

(Unaudited)

	September 30, 2008			December 31, 2007
ASSETS
Current Assets:
Cash and cash equivalents	$	30,815		$	9,615
Short-term investments		61			3,084
Accounts receivable		3,449			2,213
Inventory		4,094			2,346
Deferred cost of revenue		2,961			―
Prepaids and other assets		531			310
Total current assets		41,911			17,568
Deferred cost of revenue		―			926
Long-term investments		987			―
Property and equipment, net		2,924			2,321
Intangible assets, net		4,982			5,477
Other assets		202			170
Deferred initial public offering costs		―			2,728
Total assets	$	51,006		$	29,190

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities:
Accounts payable	$	1,012		$	1,511
Accrued compensation and employee benefits		1,774			1,033
Other accrued liabilities		2,487			2,680
Deferred revenue		8,817			50
Accrued license fee		―			3,955
Total current liabilities		14,090			9,229

Deferred revenue		83			3,311
Total liabilities		14,173			12,540
Commitments and contingencies
Redeemable convertible preferred stock:
Series A redeemable convertible preferred stock		―			4,806
Series B redeemable convertible preferred stock		―			23,102
Series C redeemable convertible preferred stock		―			31,579

Total redeemable convertible preferred stock		―			59,487
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 135,000,000 authorized as of September 30, 2008 and 60,000,000 shares authorized as of December 31, 2007; 18,171,117 and 1,870,603 shares issued and outstanding as of September 30, 2008 and December 31, 2007, respectively		18			2
Additional paid-in capital		106,147			―
Accumulated deficit		(69,357	)		(42,843	)
Accumulated other comprehensive income		25			4
Total stockholders’ equity (deficit)		36,833			(42,837	)
Total liabilities and stockholders’ equity (deficit)	$	51,006		$	29,190

See accompanying notes.

Table of Contents

MAKO SURGICAL CORP.

Condensed Statements of Operations

(in thousands, except per share data)

(Unaudited)

	Three months ended September 30,						Nine months ended September 30,
	2008			2007			2008			2007
Revenue:
Products	$	636		$	130		$	1,630		$	322
Tactile Guidance System		―			―			―			―
Other		141			20			349			33
Total revenue		777			150			1,979			355
Cost of revenue:
Products		597			37			981			88
Tactile Guidance System		611			164			1,076			187
Other		153			8			154			16
Total cost of revenue		1,361			209			2,211			291
Gross profit (loss)		(584	)		(59	)		(232	)		64
Operating costs and expenses:
Selling, general and administrative		6,265			3,394			16,032			7,696
Research and development		3,111			2,184			9,206			5,345
Depreciation and amortization		483			344			1,330			915
Total operating costs and expenses		9,859			5,922			26,568			13,956
Loss from operations		(10,443	)		(5,981	)		(26,800	)		(13,892	)
Interest and other income		241			308			642			860
Interest and other expenses		―			(77	)		(110	)		(229	)
Net loss		(10,202	)		(5,750	)		(26,268	)		(13,261	)
Accretion of redeemable convertible preferred stock		―			(76	)		(44	)		(224	)
Accrued dividends on redeemable convertible preferred stock		―			(892	)		(521	)		(2,453	)
Net loss attributable to common stockholders.	$	(10,202	)	$	(6,718	)	$	(26,833	)	$	(15,938	)
Net loss per share – Basic and diluted attributable to common stockholders	$	(0.56	)	$	(4.12	)	$	(1.76	)	$	(10.07	)
Weighted average common shares outstanding – Basic and diluted		18,149			1,631			15,266			1,582

See accompanying notes.

Table of Contents

MAKO SURGICAL CORP.

Condensed Statements of Cash Flows

(in thousands)

(Unaudited)

	Nine months ended September 30,
	2008			2007
Operating activities:
Net loss	$	(26,268	)	$	(13,261	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		1,041			455
Amortization of intangible assets		495			476
Stock-based compensation		2,668			749
Inventory write-down		595			8
Loss on asset impairment		―			14
Accrued interest expense on deferred license fee		45			224
Changes in operating assets and liabilities:
Accounts receivable		(1,236	)		(174	)
Inventory		(2,343	)		(543	)
Prepaid and other assets		(221	)		122
Other assets		(31	)		―
Accounts payable		(499	)		551
Accrued compensation and employee benefits		741			(73	)
Other accrued liabilities		(193	)		790
Deferred cost of revenue		(2,035	)		(354	)
Deferred revenue		5,539			1,348
Net cash used in operating activities		(21,702	)		(9,668	)
Investing activities:
Purchase of investments		(1,990	)		(15,357	)
Proceeds from sales and maturities of investments		4,047			10,693
Acquisition of property and equipment		(1,644	)		(1,154	)
Payment of deferred license fee on IBM license		(4,000	)		―
Acquisition of intangible assets		―			(450	)
Net cash used in investing activities		(3,587	)		(6,268	)
Financing activities:
Proceeds from initial public offering of common stock, net of underwriting fees of $3,570		47,430			―
Deferred initial public offering costs		(972	)		(1,647	)
Proceeds from issuance of Series C redeemable convertible preferred stock, net of stock issuance costs		―			29,916
Exercise of common stock options for cash		31			2
Payment of CEO payroll taxes relating to restricted common stock modification		―			(392	)
Net cash provided by financing activities		46,489			27,879
Net increase in cash and cash equivalents		21,200			11,943
Cash and cash equivalents at beginning of period		9,615			2,108
Cash and cash equivalents at end of period	$	30,815		$	14,051

Supplemental disclosures of cash flow information
Interest paid	$	2		$	―

Non-cash investing and financing activities:
Accretion of redeemable convertible preferred stock	$	44		$	224
Accrued dividends on redeemable convertible preferred stock		521			2,453
Conversion of redeemable convertible preferred stock into 10,945,080 common shares		53,667			―
Reclassification of accrued dividends on redeemable convertible preferred stock to additional paid-in capital		6,385			―
Reclassification of deferred initial public offering costs to additional paid-in capital		3,700			―
Interest on note receivable for common stock		―			4
Receipt of 35,244 shares of restricted common stock as reimbursement for payment of CEO payroll taxes.		―			392

See accompanying notes.

Table of Contents

MAKO SURGICAL CORP.

Notes to Condensed Financial Statements

September 30, 2008

(Unaudited)

1. Description of the Business

MAKO Surgical Corp. (the “Company” or “MAKO”) is a medical device company providing innovative surgical solutions to the orthopedic knee arthroplasty market. The Company was incorporated in the State of Delaware on November 12, 2004 and is headquartered in Fort Lauderdale, Florida.

In February 2008, the Company effected a one for 3.03 reverse split of its issued and outstanding common stock, which has been retroactively reflected in these condensed financial statements and notes to the condensed financial statements. Also, in February 2008, the Company completed its initial public offering (“IPO”) of common stock, issuing a total of 5.1 million shares at an issue price of $10.00 per share, resulting in net proceeds to the Company, after expenses, of approximately $43.7 million.

In conjunction with the completion of the Company’s IPO in February 2008, all of the Company’s outstanding Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock were converted into 10,945,080 shares of common stock, adjusted for the February 2008 reverse stock split. In connection therewith, all remaining redeemable convertible preferred stock discounts and accrued dividends were reclassified to additional paid-in capital and were not paid.

2. Summary of Significant Accounting Policies

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed financial statements (“condensed financial statements”) of the Company have been prepared on a basis consistent with the Company’s December 31, 2007 audited financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. These condensed financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission and, therefore, omit certain information and footnote disclosure necessary to present the statements in accordance with accounting principles generally accepted in the United States of America. These quarterly condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007 (the “Form 10-K”). The results of operations for the third quarter of 2008 may not be indicative of the results to be expected for the entire year or any future periods.

Risks and Uncertainties

The Company is subject to risks common to emerging companies in the medical device industry including, but not limited to: new technological innovations, dependence on key personnel, dependence on key suppliers, protection of proprietary technology, compliance with government regulations, uncertainty of widespread market acceptance of products, access to credit for capital purchases by our customers, product liability and the need to obtain additional financing. The Company’s products include components subject to rapid technological change. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results. While the Company has ongoing programs to minimize the adverse effect of such uncertainty and considers technological change in estimating its inventory net realizable value, uncertainty continues to exist.

Table of Contents

The Company’s current versions of its Tactile Guidance System™ (“TGS™”) and its unicompartmental implants have been cleared by the U.S. Food and Drug Administration (“FDA”). Certain products currently under development by the Company, such as future versions of its TGS and implant systems, will require clearance or approval by the FDA or other international regulatory agencies prior to commercial sale. There can be no assurance that the Company’s products will receive the necessary clearances or approvals. If the Company were to be denied such clearance or approval or such clearance or approval were delayed, it could have a material adverse impact on the Company.

The Company believes its existing cash, cash equivalents and short-term investment balances, together with the net proceeds of the financing transaction discussed in Note 8 and interest income earned on these balances, will be sufficient to meet its anticipated cash requirements for at least the next 12 months. To the extent the Company’s available cash, cash equivalents and short-term investment balances are insufficient to satisfy its operating requirements after that period, the Company will need to seek additional sources of funds, including selling additional equity or debt securities or entering into a credit facility. The sale of additional equity and debt securities may result in dilution to the Company’s current stockholders. If the Company raises additional funds through the issuance of debt securities, these securities may have rights senior to those of its common stock and could contain covenants that could restrict its operations. The Company may require additional capital beyond its currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, or at all. If the Company is unable to obtain additional financing, the Company may be required to reduce the scope of, delay or eliminate some or all of its planned research, development and commercialization activities, which could materially harm its business and results of operations.

Revenue Recognition

Revenue is generated from unit sales of the TGS, including installation services, training, upgrades and enhancements, from sales of implants and disposable products, and by providing extended warranty services. The Company’s TGS, as well as upgrades and enhancements to its TGS, include software that is essential to the functionality of the product and, accordingly, the Company accounts for the sale of the TGS pursuant to Statement of Position No. 97-2, Software Revenue Recognition (“SOP 97-2”), as amended.

The Company recognizes product revenue for sales of the TGS when there is persuasive evidence of an arrangement, the fee is fixed or determinable, collection of the fee is probable and delivery has occurred as prescribed by SOP 97-2. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. Such arrangements require the Company to provide upgrades and enhancements to the TGS unit including delivery of version 2.0 of the TGS, which is anticipated to occur in the first half of 2009, subject to regulatory clearances or approvals. All of these customer rights to receive the upgrades through version 2.0 of the TGS are on a when and if available basis.

For arrangements with multiple elements, the Company allocates arrangement consideration to TGS units, upgrades, enhancements and services based upon vendor specific objective evidence (“VSOE”) of fair value of the respective elements. VSOE of fair value does not yet exist for all the undelivered elements; however, the Company is gathering information and believes it will have established VSOE in the first half of 2009. Accordingly, all revenue and direct cost of revenue associated with the sale of the TGS are deferred until the earlier of (1) delivery of all elements or (2) establishment of VSOE of fair value for all undelivered elements.

Sales on TGS units are currently recorded as deferred revenue. The direct cost of revenue associated with the sale of TGS units is currently recorded as deferred cost of revenue. Costs associated with establishing an accrual for the TGS standard one-year warranty liability and royalties related to the sale of TGS units covered by licensing arrangements are expensed as incurred and included in Cost of Revenue, Tactile Guidance System, in the condensed statements of operations. The Company anticipates ultimately recognizing a positive margin on the sales to date of TGS units, including the satisfaction of the remaining upgrades through the final deliverable of version 2.0 of the TGS, which is anticipated to be in the first half of 2009. As recognition of the deferred revenue and deferred cost of revenue balances associated with sales of TGS units are anticipated to occur within 12 months of September 30, 2008, the Company classified these balances as current liabilities and current assets, respectively, as of September 30, 2008. If the Company is not able to deliver version 2.0 of the TGS, customers would retain the original TGS unit sold and the Company would not be obligated to refund the purchase price of the TGS unit.

Table of Contents

Product revenue from the sale of implants and disposable products (the “Products”) is recognized as revenue in accordance with Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition , when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectibility is reasonably assured. The Products are a separate unit of accounting from the TGS as (1) they have value to the customer on a standalone basis, (2) objective and reliable evidence of the fair value of the item exists and (3) no right of return exists once the Products are implanted or consumed. Accordingly, as the Company’s implants and disposable products are sold on a procedural basis, the revenue and costs associated with the sale of Products are recognized at the time of sale (i.e., at the time of the completion of the related surgical procedure).

Service revenue, which is included in other revenue, consists of extended warranty services on the TGS hardware, is deferred and recognized ratably over the service period until no further obligation exists. Costs associated with providing services are expensed when incurred.

Deferred Revenue and Deferred Cost of Revenue

Deferred revenue consists of deferred product revenue and deferred service revenue. Deferred product revenue arises from timing differences between the shipment of product and satisfaction of all revenue recognition criteria consistent with the Company’s revenue recognition policy. Deferred service revenue results from the advance payment for services to be delivered over a period of time, usually in one-year increments. Service revenue is recognized ratably over the service period. Deferred cost of revenue consists of the direct costs associated with the manufacture of TGS units for which the revenue has been deferred in accordance with the Company’s revenue recognition policy. Deferred revenue and associated deferred cost of revenue expected to be realized within one year are classified as current liabilities and current assets, respectively.

Intangible Assets

The Company’s intangible assets are comprised of a purchased patent application and licenses to intellectual property rights. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded using the straight-line method, over their respective useful lives (generally the life of underlying patents), which range from approximately 10 to 19 years.

Deferred Initial Public Offering Costs

Specific incremental costs directly associated with the Company’s IPO, primarily legal, accounting and printing costs, were deferred and reflected as an asset until reclassification to stockholders’ equity (deficit) upon closing of the IPO in February 2008.

Net Loss Per Share

The Company calculated net loss per share in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 128, Earnings per Share . Basic earnings per share (“EPS”) is calculated by dividing the net income or loss available to common stockholders adjusted for redeemable convertible preferred stock accretion and dividends by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period and the weighted average number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

Table of Contents

(in thousands)	September 30,
	2008	2007
Stock options outstanding	2,188	1,921
Warrants to purchase common stock	463	463
Redeemable convertible preferred stock	―	33,164

Recent Accounting Pronouncements

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“SFAS 157”). SFAS 157 defines fair value, provides a consistent framework for measuring fair value under accounting principles generally accepted in the United States and expands fair value financial statement disclosure requirements. SFAS 157 does not require any new fair value measurements. It only applies to accounting pronouncements that already require or permit fair value measures, except for standards that relate to stock-based payments.

SFAS 157’s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. SFAS 157 classifies these inputs into the following hierarchy:

•

Level 1 Inputs–Quoted prices for identical instruments in active markets.

•

Level 2 Inputs–Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

•

Level 3 Inputs–Instruments with primarily unobservable value drivers.

SFAS 157 is effective for fiscal years beginning after November 15, 2007. Effective January 1, 2008, the Company adopted the provisions of SFAS 157. The adoption of SFAS 157 did not have a material impact on the Company’s results of operations and financial condition.

Effective January 1, 2008, the Company adopted SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115 (“SFAS 159”) and has not elected to use fair value measurement on any assets or liabilities under this statement. The Company has determined that the adoption of SFAS 159 had no effect on its results of operations and financial position.

Effective January 1, 2008, the Company adopted Emerging Issues Task Force (“EITF”) Issue No. 07-03, Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities (“EITF 07-03”). EITF 07-03 requires that nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. Such amounts should be recognized as an expense as the related goods are delivered or the related services are performed. Entities should continue to evaluate whether they expect the goods to be delivered or services to be rendered. If an entity does not expect the goods to be delivered or services to be rendered, the capitalized advance payment should be charged to expense. The Company has determined that the adoption of EITF 07-03 had no effect on its results of operations and financial position.

In June 2008, the EITF issued Issue No. 07-05, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock (“EITF 07-05”). EITF 07-05 addresses the determination of whether an instrument (or an embedded feature) is indexed to an entity’s own stock, if an instrument (or an embedded feature) that has the characteristics of a derivative instrument is indexed to an entity’s own stock, it is still necessary to evaluate whether it is classified in stockholders’ equity (or would be classified in stockholders’ equity if it were a freestanding instrument). In addition, for some instruments that are potentially subject to the guidance in EITF Issue No. 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock , but do not have all the characteristics of a derivative instrument under paragraphs 6 through 9, it is still necessary to evaluate whether it is classified in stockholders’ equity. It is effective for financial statements issued for fiscal years beginning after December 15, 2008. The Company is currently evaluating the impact that EITF 07-05 will have on its financial statements.

Table of Contents

In December 2007, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 141 (revised 2007), Business Combinations (“SFAS 141(R)”). SFAS 141(R) retains the fundamental requirements of the original pronouncement requiring that the purchase method be used for all business combinations. SFAS 141(R) defines the acquirer as the entity that obtains control of one or more businesses in the business combination, establishes the acquisition date as the date that the acquirer achieves control and requires the acquirer to recognize the assets acquired, liabilities assumed and any noncontrolling interest at their fair values as of the acquisition date. SFAS 141(R) also requires that acquisition-related costs be recognized separately from the acquisition. SFAS 141(R) will become effective for the Company on January 1, 2009. The Company is currently evaluating the impact that SFAS 141(R) will have on its financial statements.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements (“SFAS 160”). SFAS 160 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the noncontrolling interest, changes in a parent’s ownership interest and the valuation of retained noncontrolling equity investments when a subsidiary is deconsolidated. SFAS 160 also establishes reporting requirements that provide sufficient disclosures that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS 160 will become effective for the Company beginning in the first quarter of 2009. The Company is currently evaluating the impact that SFAS 160 will have on its financial statements.

In October 2008, the FASB issued Staff Position No. FAS 157-3, Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active (“FSP 157-3”) which clarifies the application of SFAS 157 in an inactive market and illustrates how an entity would determine fair value when the market for a financial asset is not active. FSP 157-3 is effective immediately and applies to prior periods for which financial statements have not been issued, including interim or annual periods ending on or before September 30, 2008. The implementation of FAS 157-3 did not have a material impact on the Company’s financial statements.

Reclassifications

Certain reclassifications have been made to the prior periods’ condensed statements of operations and condensed statements of cash flows to conform to the current period’s presentation.

3. Investments

The Company’s investments are classified as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses included in other comprehensive income within stockholders’ equity (deficit). Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in interest and other expenses. Interest and dividends on securities classified as available-for-sale are included in interest and other income. The cost of securities sold is based on the specific identification method.

The amortized cost and fair value of short and long-term investments, with gross unrealized gains and losses, were as follows:

Table of Contents

As of September 30, 2008

(in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Short-term investments:
Certificates of deposit	$	61	$	―	$		$	61
Long-term investments:
Variable auction rate securities		962		25		―		987
Total investments	$	1,023	$	25	$	―	$	1,048

As of December 31, 2007

(in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Short-term investments:
Variable auction rate securities	$	1,550	$	―	$	―	$	1,550
U.S. treasury bills		1,505		4		―		1,509
Certificates of deposit		25		―		―		25
Total short-term investments	$	3,080	$	4	$	―	$	3,084

As of September 30, 2008 and December 31, 2007, all short-term investments have maturities or interest reset dates of less than one year.

The fair values of the Company’s investments based on the level of inputs are summarized below:

(in thousands)			Fair Value Measurements at the Reporting Date Using
	September 30, 2008		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Short-term investments:
Certificates of deposit	$	61	$	61	$	―	$	―
Long-term investments:
Variable auction rate securities		987		―		―		987
Total investments	$	1,048	$	61	$	―	$	987

As of September 30, 2008, the Company held $1,025,000 par value of variable auction rate securities issued by two separate funds. In February 2008, the auction rate securities experienced failed auctions that limited the liquidity of these securities. Based on current market conditions, it is likely that auction failures will continue. Historically, the fair value of auction rate securities approximated par value due to the frequent resets through the auction rate process. The uncertainty in the credit markets affected the Company’s holdings in auction rate securities and the liquidity and fair value of these investments has been negatively impacted. An other-than-temporary impairment charge of $63,000 was recorded in the first quarter of 2008 to reduce the value of its auction rate securities to the new fair value. As of September 30, 2008, the auction rate securities were recorded at the estimated fair value of $987,000. In addition, as a result of the unresolved liquidity concerns, the Company reclassified its auction rate securities from short-term investments to long-term investments in 2008. The Company’s investment firm has informed the Company that it currently intends to redeem its auction rate securities in early 2009 at par value. Based on current market conditions and uncertainty of future conditions, however, the Company believes long-term classification remains appropriate. The carrying value of the securities are fully collateralized by assets held by the funds and were rated AAA prior to the failed auctions of the securities.

Table of Contents

The Company used a discounted cash flow model to determine the estimated fair value of its auction rate securities in 2008. The assumptions used in preparing the discounted cash flow model included estimates for interest rates, timing and amount of cash flows and expected holding periods of the auction rate securities. These assumptions are subject to uncertainties, are difficult to predict and require significant judgment. The use of different assumptions could result in significantly different estimates of fair value. The fair value of the Company’s auction rate securities could change significantly based on market conditions and continued uncertainties in the credit markets. If these uncertainties continue or if these securities experience credit rating downgrades, the Company may incur additional impairment on its auction rate securities. The Company will continue to monitor the fair value of its auction rate securities and relevant market conditions and may record additional impairment charges if future circumstances warrant such charges.

The table below provides a reconciliation of auction rate securities assets measured at fair value on a recurring basis which use Level 3 or significant unobservable inputs for the three and nine months ended September 30, 2008.

(in thousands)	Fair Value Measurements Using Significant Unobservable Inputs
	Three Months Ended September 30, 2008		Nine Months Ended September 30, 2008
Balance at beginning of period	$	962	$	―
Transfers into Level 3		―		1,550
Total losses realized included in earnings		―		(63	)
Total unrealized gains included in other comprehensive income		25		25
Sales/Redemptions		―		(525	)
Balance at September 30, 2008.	$	987	$	987

The total amount of gains or losses for the period included in earnings attributable to the change in unrealized gains or losses relating to assets still held at the reporting date	$	―	$	(63	)

4. Inventory

Inventory consisted of the following:

(in thousands)	September 30, 2008		December 31, 2007

Raw materials	$	2,264	$	974
Work-in-process		413		642
Finished goods		1,417		730
Total inventory	$	4,094	$	2,346

Table of Contents

The Company developed a MAKO-branded unicompartmental implant system called RESTORIS®, which launched in the third quarter of 2008. The Company is also developing version 2.0 of its TGS, which is anticipated to launch in the first half of 2009. In conjunction with the launch of RESTORIS and the anticipated launch of version 2.0 of the TGS, the Company is discontinuing portions of its current implant lines and the current version of its TGS. The Company incurred write-offs totaling approximately $595,000 during the nine months ended September 30, 2008 as follows:

•

Approximately $291,000 of obsolete inventory due to the discontinuation of the Company’s current implant lines in connection with the launch of the RESTORIS implant system;

•

Approximately $232,000 of obsolete inventory due to the discontinuation of the Company’s current version of its TGS in anticipation of the launch of version 2.0 of the Company’s TGS; and

•

Approximately $72,000 of other write-offs.

Depending on demand for the Company’s products and technical obsolescence, additional future write-offs of the Company’s inventory may occur.

5. Commitments and Contingencies

IBM License Agreement

In March 2006, the Company entered into an agreement with International Business Machines Corporation (“IBM”) to license, in the Company’s field of business, IBM’s patent portfolio in exchange for a payment of $2 million upon execution of the agreement and a deferred payment of $4 million payable upon a change of control, as defined in the agreement (including, but not limited to, an initial public offering of the Company’s common stock) (the “Deferred License Fee”). Upon completion of the Company’s IPO in February 2008, the Company paid the $4 million Deferred License Fee due to IBM.

Purchase Commitments

At September 30, 2008, the Company was committed to make future purchases for inventory related items under various purchase arrangements with fixed purchase provisions aggregating approximately $5.7 million.

Contingencies

In November 2007, the Company received a letter from counsel to SensAble Technologies, Inc. (“SensAble”), a licensor to the Company, alleging that the Company infringed certain of its patents and breached a confidentiality provision in the license agreement between SensAble and the Company dated May 2006 (the “SensAble License Agreement”). In the letter, SensAble alleged, among other things, that the Company exceeded the scope of its licensed field of computer-assisted surgery by using its technology for, among other things, pre-operative planning and post-operative follow-up. SensAble also alleged that the Company’s TGS infringed one or more claims in five U.S. patents that are not among the patents licensed to the Company pursuant to the SensAble License Agreement.

The Company investigated SensAble’s allegations, and, based on the opinion of external counsel, it believes that if SensAble initiates a lawsuit against the Company, a court should find that its TGS does not infringe any of the SensAble patents identified in the November 2007 letter. The Company communicated its belief to SensAble. SensAble has not commenced any legal action against the Company, but may do so in the future. The letter from counsel to SensAble stated that unless the Company, among other things, ceases and desists from alleged infringement of SensAble’s patents or pays additional licensing fees, including a proposed licensing fee of $30 million for additional patents not included in the SensAble License Agreement, SensAble intends to bring a lawsuit against the Company. The Company intends to vigorously defend itself against these allegations in the event of a lawsuit. The Company cannot predict the outcome of this matter at this time.

Table of Contents

The Company has been a party to other legal contingencies or claims arising in the normal course of business, none of which the Company believes is material to its financial position, results of operations or cash flows.

6. Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

Redeemable Convertible Preferred Stock

As of September 30, 2008, the Company was authorized to issue 27,000,000 shares of $0.001 par value preferred stock. As of September 30, 2008, there were no shares of preferred stock issued or outstanding. All shares of Series A, Series B and Series C redeemable convertible preferred stock that were issued and outstanding as of December 31, 2007 converted into 10,945,080 shares of common stock upon closing of the Company’s IPO in February 2008.

Common Stock

As of September 30, 2008, the Company was authorized to issue 135,000,000 shares of $0.001 par value common stock. As of December 31, 2007, the Company was authorized to issue 60,000,000 shares of $0.001 par value common stock. Common stockholders are entitled to dividends as and if declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.

In December 2004, the Company issued 189,768 shares of restricted common stock to certain consultants (the “Consultant Restricted Stock”). The Consultant Restricted Stock vested in tranches upon the Company’s achievement of certain business milestones and any unvested restricted stock vested immediately upon completion of an initial public offering of common stock. Upon vesting, the Company recorded a consulting expense equal to the estimated fair value of the Company’s common stock on the date of vesting. As of January 1, 2008, 94,884 shares of the Consultant Restricted Stock were unvested. Upon closing of the IPO in February 2008, the vesting of the remaining 94,884 shares of Consultant Restricted Stock was accelerated and the Company recognized $949,000 of compensation expense associated with the accelerated vesting of the Consultant Restricted Stock during the nine months ended September 30, 2008 based on the IPO price of $10.00 per share.

See Note 8 for additional disclosure regarding the issuance of common stock in connection with the Company’s October 2008 financing transaction.

Comprehensive Loss

Comprehensive loss is defined as the change in equity from transactions and other events and circumstances other than those resulting from investments by owners and distributions to owners. For the three months ended September 30, 2008 and 2007, the Company recorded comprehensive losses of approximately $10,184,000 and $5,735,000, respectively. For the nine months ended September 30, 2008 and 2007, the Company recorded comprehensive losses of approximately $26,247,000 and $13,252,000, respectively.

Stock Option Plans and Stock-Based Compensation

The Company recognizes compensation expense for its stock-based awards in accordance with SFAS No. 123 Revised, Share-Based Payment (“SFAS 123(R)”). SFAS 123(R) requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options. SFAS 123(R) requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model.

During the three months ended September 30, 2008 and 2007, stock-based compensation expense was $609,000 and $599,000, respectively. Included within stock-based compensation expense for the three months ended September 30, 2008 were $382,000 related to stock option grants and $227,000 related to the partial vesting of 741,075 shares of restricted stock granted to the Company’s CEO at various dates from 2005 through 2007. During the nine months ended September 30, 2008 and 2007, stock-based compensation expense was $2,668,000 and $749,000, respectively. Included within stock-based compensation expense for the nine months ended September 30, 2008 were $1,039,000 related to stock option grants, $680,000 related to the partial vesting of 741,075 shares of restricted stock granted to the Company’s CEO at various dates from 2005 through 2007, and $949,000 related to the vesting of the Consultant Restricted Stock.

Table of Contents

The Company’s 2004 Stock Incentive Plan (the “2004 Plan”) is described in the Form 10-K. In January 2008, the Company’s Board of Directors and stockholders approved the MAKO Surgical Corp. 2008 Omnibus Incentive Plan (the “2008 Plan,” and together with the 2004 Plan, the “Plans”). The 2008 Plan became effective upon the closing of the IPO and will expire January 9, 2018 unless earlier terminated by the Board of Directors. The aggregate number of shares of the Company’s common stock that may be issued initially pursuant to stock awards under the 2008 Plan is 1,084,703 shares, which includes approximately 85,000 shares previously reserved but unallocated under the 2004 Plan. Awards under the 2008 Plan may be made in the form of: stock options, which may be either incentive stock options or non-qualified stock options; stock appreciation rights; restricted stock; restricted stock units; dividend equivalent rights; performance shares; performance units; cash-based awards; other stock-based awards, including unrestricted shares; and any combination of the foregoing.

Generally, the Company’s outstanding stock options vest over four years. However, certain stock options granted in 2004 vested on the date of grant. Stock options granted to certain non-employee directors generally vest over three years. Continued vesting typically terminates when the employment or consulting relationship ends. Vesting generally begins on the date of grant; however, certain stock options granted in 2007 began vesting upon the achievement of performance conditions.

Under the terms of the Plans, the maximum term of options intended to be incentive stock options granted to persons who own at least 10% of the voting power of all outstanding stock on the date of grant is 5 years. The maximum term of all other options is 10 years. Options issued under the 2008 Plan that are forfeited or expire will again be made available for issuing grants under the 2008 Plan. Options issued under the 2004 Plan that are forfeited or expire will not be made available for issuing grants under the 2008 Plan. All future options granted will be issued under the Company’s 2008 Plan.

Activity under the Plans is summarized as follows:

(in thousands, except per share data)			Outstanding Options
	Shares/Options Available For Grant		Number of Options		Weighted Average Exercise Price
Balance at December 31, 2007	85		1,917		$	4.81
Shares reserved	1,000		―			―
Options granted	(323	)	323			8.87
Options exercised	―		(40	)		0.78
Options forfeited the 2004 Plan	―		(10	)		7.48
Options forfeited under the 2008 Plan	2		(2	)		9.30
Balance at September 30, 2008	764		2,188			5.58

Included in the 2008 stock option grants in the table above are 198,019 incentive stock options the Company granted to its CEO upon the completion of its IPO in February 2008.

As of September 30, 2008, there was total unrecognized compensation cost of approximately $4,779,000, adjusted for estimated forfeitures, related to non-vested stock-based payments granted to the Company’s employees and non-employee directors. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures, and is expected to be recognized over a remaining weighted average period of 2.14 years as of September 30, 2008.

Table of Contents

The estimated grant date fair values of the stock option grants were calculated using the Black-Scholes-Merton valuation model, based on the following assumptions:

	Nine Months Ended September 30,
	2008	2007
Risk-free interest rate	3.44% - 3.62%	4.50% - 5.14%
Expected life	6.25 years	6.25 years
Expected dividends	―	―
Expected volatility	56.49% - 56.78%	56.24% - 60.00%

Employee Stock Purchase Plan

In January 2008, the Company’s Board of Directors and stockholders approved the MAKO Surgical Corp. 2008 Employee Stock Purchase Plan (the “2008 Employee Stock Purchase Plan”). The 2008 Employee Stock Purchase Plan became effective upon closing of the IPO. The 2008 Employee Stock Purchase Plan authorizes the issuance of 625,000 shares of the Company’s common stock for purchase by eligible employees of the Company or any of its participating affiliates. The shares of common stock issuable under the 2008 Employee Stock Purchase Plan may be authorized but unissued shares, treasury shares or shares purchased on the open market. The purchase price for a purchase period may not be less than 85% of the fair market value of the Company’s common stock on the first trading day of the applicable purchase period or the last trading day of such purchase period, whichever is lower. The initial purchase period of the 2008 Employee Stock Purchase Plan began on October 1, 2008. No shares were issued under the 2008 Employee Stock Purchase Plan during the nine months ended September 30, 2008; however, shares will be issued upon the expiration of the initial purchase period on December 31, 2008.

Warrants

In December 2004, the Company issued warrants to purchase 462,716 shares of common stock at a purchase price of $0.03 per share. The warrants are immediately exercisable at an exercise price of $3.00 per share (after giving effect to the one for 3.03 reverse split of the Company’s common stock), and expire in December 2014. As of September 30, 2008, all the warrants were outstanding and exercisable and none had been exercised.

See Note 8 for additional disclosure regarding the issuance of warrants in connection with the Company’s October 2008 financing transaction.

7. Income Taxes

The Company accounts for income taxes under SFAS No. 109, Accounting for Income Taxes . Deferred income taxes and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

Due to uncertainty surrounding realization of the deferred income tax assets in future periods, the Company has recorded a 100% valuation allowance against its net deferred income tax assets. If it is determined in the future that it is more likely than not that the deferred income tax assets are realizable, the valuation allowance will be reduced.

In July 2006, the FASB issued Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes . FIN 48 clarifies the accounting for uncertainty in income taxes by prescribing the recognition threshold a tax position is required to meet before being recognized in the financial statements. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company adopted the provisions of FIN 48 effective January 1, 2007. The adoption of this statement did not result in a cumulative accounting adjustment and did not impact the Company’s financial position, results of operations or cash flows. In accordance with FIN 48, paragraph 19, the Company has decided to classify any interest and penalties as a component of tax expense. As of September 30, 2008, the Company had no unrecognized tax benefits. To date, there have been no interest or penalties charged to the Company in relation to the underpayment of income taxes. The Company files federal and state income tax returns in several jurisdictions in the United States. The tax years from 2004 through 2007 remain open and are subject to examination by the appropriate governmental agencies.

Table of Contents

8. Subsequent Events

In October 2008, the Company entered into a Securities Purchase Agreement for an equity financing of up to $60 million, with initial gross proceeds of $40 million, which the Company closed on October 31, 2008, and conditional access to an additional $20 million (the “Second Closing”). In connection with the financing, the Company issued and sold to the participating investors 6,451,613 shares of its common stock at a purchase price of $6.20 per share and issued warrants to the participating investors to purchase 1,290,323 shares of common stock at an exercise price of $7.44 per share. The warrants will become exercisable 180 days from issuance and have a seven-year term. Subject to the Company’s satisfaction of certain business related milestones before December 31, 2009, and approval of the Second Closing by the Company’s stockholders, the Company will have the right to require certain participants in the financing to purchase an additional $20 million of common stock and warrants to purchase common stock. At the initial closing, the investors that agreed to provide the additional $20 million investment received warrants to purchase an additional 322,581 shares of common stock at an exercise price of $6.20 per share. These warrants will not be exercisable until the earlier of the Second Closing or December 31, 2009.

The participating investors consisted of eleven accredited investors, seven of which were existing stockholders of the Company, namely Ziegler Meditech Equity Partners LP, an affiliate of MK Investment Company, two entities affiliated with Lumira Capital Corp., an entity affiliated with Aperture Venture Partners, and two members of the Company’s Board of Directors, Christopher C. Dewey and Frederic H. Moll, M.D., all of whom (except for the affiliate of Aperture Venture Partners) were deemed to be affiliates of the Company by virtue of their being represented on the Company’s Board of Directors or, in the case of Mr. Dewey and Dr. Moll, by virtue of their Board membership. The remaining four participants are affiliated with venture firms that were not Company stockholders prior to the closing of the financing, namely Montreux Equity Partners IV, L.P. and Montreux IV Associates, L.L.C., Skyline Venture Partners V, L.P., and Alta Partners VIII, LP.

Table of Contents

Item 2. MANAGEMENT ’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

In this report, “MAKO Surgical”, “MAKO”, the “Company,” “we,” “us” and “our” refer to MAKO Surgical Corp.

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed financial statements and related notes appearing elsewhere in this report. This report contains forward-looking statements regarding, among other things, statements related to expectations, goals, plans, objectives and future events. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Examples of such statements include, but are not limited to, statements about the timing and number of planned new product introductions, market acceptance of the MAKOplasty ® solution, the future availability of implants and components of our Tactile Guidance System™, or TGS™, from third-party suppliers, including single-source suppliers, the anticipated adequacy of our capital resources to meet the needs of our business, our ability to sustain, and our goals for, sales and earnings growth and our success in achieving timely approval or clearance of products with domestic and foreign regulatory entities. These statements are based on the current estimates and assumptions of our management as of the date of this report and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements, many of which are beyond our ability to control or predict. Such factors, among others, may have a material adverse effect on our business, financial condition and results of operations and may include the potentially significant impact of an economic downturn on the ability of our customers to secure adequate funding to buy our products or cause our customers to delay a purchasing decision, changes in competitive conditions and prices in our markets, decreases in sales of our principal product lines, increases in expenditures related to increased governmental regulation of our business, loss of key management and other personnel or inability to attract such management and other personnel, unanticipated intellectual property expenditures required to develop and market our products and unanticipated issues in securing regulatory clearance or approvals for upgrades or changes to our products. These and other risks are described in greater detail under Item 1A, “Risk Factors,” contained in our annual report on Form 10-K, or Form 10-K, filed with the Securities and Exchange Commission, or SEC, on March 31, 2008. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We do not undertake any obligation to release any revisions to these forward-looking statements publicly to reflect events or circumstances in the future, even if new information becomes available.

“MAKOplasty®,” “Tactile Guidance System™,” “TGS ™ ” and “RESTORIS®,” as well as the “MAKO” logo, whether standing alone or in connection with the words “MAKO Surgical Corp.” are trademarks of MAKO Surgical Corp.

Overview

We are a medical device company that markets our advanced robotic-arm solution and orthopedic implants for minimally invasive orthopedic knee procedures. We offer MAKOplasty, an innovative, restorative surgical solution that enables orthopedic surgeons to consistently, reproducibly and precisely treat patient-specific, early to mid-stage osteoarthritic knee disease. In February 2008, our common stock began trading on The NASDAQ Global Market under the ticker symbol “MAKO” and we closed our initial public offering, or IPO.

Through September 30, 2008, our revenue was primarily generated from the sale of our implants and disposable products utilized in MAKOplasty procedures. In accordance with our revenue recognition policy, upon customer acceptance of the sale of our TGS, we defer recognition of the related revenue and cost of revenue until delivery of version 2.0 of the TGS, which is anticipated in the first half of 2009, subject to regulatory clearances or approvals. We have incurred net losses in each year since our inception and, as of September 30, 2008, we had an accumulated deficit of $69.4 million. We expect to continue to incur significant operating losses as we increase our sales and marketing activities and otherwise continue to invest capital in the development and expansion of our products and our business generally. We also expect that our general and administrative expenses will increase due to additional operational and regulatory costs and burdens associated with operating as a public company and due to the rapid expansion of our operations.

Table of Contents

Recent key milestones and goals in the development of our business through September 30, 2008 include the following:

• In January 2008, we obtained 510(k) marketing clearance from the FDA for version 1.2 of our TGS and commercially launched version 1.2 of our TGS in the first quarter of 2008.

• In February 2008, we completed the IPO of our common stock, issuing a total of 5.1 million shares at an issue price of $10.00 per share, resulting in net proceeds to the Company of approximately $43.7 million, after underwriting discounts and commissions of $3.6 million and expenses of approximately $3.7 million.

• In the second quarter of 2008, we filed a 510(k) submission with the FDA for version 2.0 of our TGS. We also received a 510(k) clearance for our unicompartmental implant and a 510(k) clearance for our patellofemoral implant, components of our intended bicompartmental implant strategy.

• In the third quarter of 2008, we finalized development of a TGS software application to enable our MAKO-branded RESTORIS unicompartmental implant system, combining our inlay and onlay system. We commercially introduced this software, version 1.3 of our TGS, and RESTORIS in the third quarter of 2008. We have received a 510(k) clearance for the RESTORIS implant system. TGS version 1.3 did not require a 510(k) clearance as the indications for use of RESTORIS with the TGS were included and cleared as part of version 1.2 of our TGS.

• We are currently developing version 2.0 of our TGS and our modular bicompartmental knee implant system, which would enable both unicompartmental and bicompartmental knee resurfacing procedures. We anticipate that we will commercially introduce version 2.0 of the TGS and the bicompartmental implant system in the first half of 2009, subject to regulatory clearances or approvals. If we were to be denied such clearances or approvals, if such clearances or approvals were delayed or if the required development is unsuccessful or delayed, it could have a material adverse impact on our results of operations.

We believe that the key to growing our business is expanding the application of MAKOplasty to bicompartmental resurfacing procedures by offering implants that address mid-stage, bicompartmental degeneration. To successfully commercialize our products and grow our business, we must gain market acceptance for MAKOplasty.

Factors Which May Influence Future Results of Operations

The following is a description of factors which may influence our future results of operations, including significant trends and challenges that we believe are important to understanding our business and results of operations.

Table of Contents

Revenue

Revenue is generated from unit sales of our TGS, including installation services, training and upgrades and enhancements, from sales of implants and disposable products, and by providing extended warranty services. To date, we have generated revenue primarily from the sale of implants and disposable products utilized in MAKOplasty procedures, the majority of which was from several significant customers. Recognition of revenue associated with the sale of TGS units in our statements of operations is dependent upon satisfying all related revenue recognition criteria, which include the delivery of version 2.0 of the TGS, which is anticipated to be in the first half of 2009, subject to regulatory clearances or approvals, as more fully described in Item 1, Financial Statements, Note 2 to the Condensed Financial Statements.

Future revenue from sales of our products is difficult to predict and we expect that it will only modestly reduce our continuing and increasing losses resulting from selling, general and administrative expenses, research and development and other activities for the next several years. Our future revenue may also be adversely affected by the current general economic downturn and the resulting tightening of the credit markets, which may cause our customers to experience difficulties in securing adequate funding to buy our products or cause purchasing decisions to be delayed.

The generation of recurring revenue through sales of our implants, disposable products and service contracts are an important part of the MAKOplasty business model. We anticipate that recurring revenue will constitute an increasing percentage of our total revenue as we leverage each new installation of our TGS to generate recurring sales of implants and disposable products and as we expand our implant product offering.

Cost of Revenue

Cost of revenue primarily consists of the direct costs associated with the manufacture of TGS units, implants and disposable products for which revenue has been recognized in accordance with our revenue recognition policy. Costs associated with providing services are expensed as incurred. Cost of revenue also includes the cost associated with establishing at the time of installation an accrual for the TGS standard one-year warranty liability, royalties related to the sale of products covered by licensing arrangements and write-offs of obsolete or impaired inventory.

The cost of revenue associated with the sale of TGS units is deferred until the recognition of the related revenue. In addition, we expect that deferred costs of revenue associated with the sale of TGS units will be higher during the deferral period due to the additional costs associated with providing hardware enhancements and upgrades through and including the anticipated delivery of version 2.0 of our TGS.

In the third quarter of 2008, we commercially introduced the RESTORIS implant system, our MAKO-branded unicompartmental implant system. We are also developing version 2.0 of our TGS, which is anticipated to launch in the first half of 2009. In conjunction with the launch of RESTORIS and the anticipated launch of version 2.0 of the TGS, we are discontinuing portions of our current implant line and the current version of our TGS. As a result, we wrote-off inventory totaling approximately $523,000 during the quarter ended September 30, 2008 relating to these product transitions. Depending on demand for our products and technical obsolescence, additional future write-offs of our inventory may occur.

Selling, General and Administrative Expenses

Our selling, general and administrative expenses consist primarily of compensation, including stock-based compensation, for sales, marketing, operations, regulatory, quality, executive, finance, legal and administrative personnel. Other significant expenses include costs associated with sales and marketing activities, marketing and advertising materials, professional fees for legal and accounting services, consulting fees, travel expenses, facility and related operating costs, and recruiting expenses. Our selling, general and administrative expenses are expected to continue to increase due to the cost associated with the expected commercial launch of version 2.0 of our TGS, our bicompartmental implant system and disposable products, an increased number of employees necessary to support our continued growth in operations, and the additional operational and regulatory burdens and costs associated with operating as a publicly traded company. In addition, we are currently taking preliminary steps to investigate the feasibility of establishing clinical sites outside the United States, which may also increase our selling, general and administrative expenses, and we expect to incur additional costs associated with securing and protecting our intellectual property rights as necessary to support our future product offerings.

Table of Contents

Research and Development Expenses

Costs related to research, design and development of products are charged to research and development expense as incurred. These costs include direct salary costs for research and development employees including stock-based compensation, cost for materials used in research and development activities and costs for outside services. Research and development expenses are expected to continue to increase as we develop version 2.0 of our TGS and our bicompartmental implant system and research of potential future products.

Critical Accounting Policies

A summary of our critical accounting policies is included in our Form 10-K, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” There have been no changes to those policies for the nine months ended September 30, 2008.

Results of Operations

Comparison of the Three Months Ended September 30, 2008 to the Three Months Ended September 30, 2007

Revenue. Revenue was $777,000 for the three months ended September 30, 2008, compared to $150,000 for the three months ended September 30, 2007, and was primarily generated from the sale of implants and disposable products utilized in MAKOplasty procedures. The increase in revenue of $627,000 was primarily due to an increase in MAKOplasty procedures performed during the three months ended September 30, 2008 as compared with the three months ended September 30, 2007. There were 159 procedures performed during the three months ended September 30, 2008, compared to 29 procedures performed during the three months ended September 30, 2007. The increase was also attributable to a $121,000 increase in other revenue, which consists primarily of service revenue on extended warranty services and net royalty revenue. We expect our revenue to increase as the number of MAKOplasty procedures performed increases in future periods. The deferred revenue balance was $8.9 million and $2.0 million as of September 30, 2008 and 2007, respectively. The deferred revenue balance primarily consisted of the deferred revenue associated with the sale of thirteen and three unit sales of our TGS, as of September 30, 2008 and 2007, respectively. Deferred revenue related to unit sales of our TGS will be recognized in our statement of operations if and when we have satisfied all related revenue recognition criteria. The criteria include the delivery of version 2.0 of the TGS, which is anticipated to be in the first half of 2009, subject to regulatory clearances or approvals.

Cost of Revenue. Cost of revenue was $1.4 million for the three months ended September 30, 2008, compared to $209,000 for the three months ended September 30, 2007. The increase in cost of revenue of $1.2 million was primarily due to an increase in MAKOplasty procedures performed, a $523,000 write-off of discontinued inventory in the third quarter of 2008 due to the launch of our RESTORIS implant system and anticipated launch of version 2.0 of our TGS, the establishment of warranty accruals on sales of three TGS units and royalties incurred on sales of three TGS units during the three months ended September 30, 2008. The increase was also attributable to a $145,000 increase in other cost revenue consisting primarily of depreciation on a rental TGS and $97,000 of supply chain cancellation charges. We expect our cost of revenue to increase as the number of MAKOplasty procedures performed increases in future periods. In addition, anticipated increases in sales of our TGS units will result in an increase in royalty and warranty expense. The deferred cost of revenue balance was $3.0 million and $564,000 as of September 30, 2008 and 2007, respectively. The increase in the deferred cost of revenue balance is primarily related to unit sales of our TGS during 2008 and 2007. Deferred cost of revenue related to unit sales of our TGS will be recognized in our statement of operations if and when we have satisfied all related revenue recognition criteria. The criteria include the delivery of version 2.0 of the TGS, which is anticipated to be in the first half of 2009, subject to regulatory clearances or approvals.

Table of Contents

Selling, General and Administrative. Selling, general and administrative expense was $6.3 million for the three months ended September 30, 2008, compared to $3.4 million for the three months ended September 30, 2007. The increase of $2.9 million, or 85%, was primarily due to an increase in sales, marketing and operations costs associated with the production and commercialization of our products, an increase in general and administrative costs to support growth and costs associated with operating as a public company and costs associated with the accrual for employee bonus compensation plans covering substantially all of the employees of the Company. We expect our selling, general and administrative expense to continue to increase substantially due to our planned increase in the number of employees necessary to support the sales and marketing efforts associated with the growing commercialization of MAKOplasty, the anticipated commercial launch of version 2.0 of our TGS in the first half of 2009, subject to regulatory clearances or approvals, continued growth in operations and the costs associated with operating as a public company.

Research and Development. Research and development expense was $3.1 million for the three months ended September 30, 2008, compared to $2.2 million for the three months ended September 30, 2007. The increase of $927,000, or 42%, was primarily due to an increase in research and development activities associated with on-going development of version 2.0 of our TGS and the MAKO RESTORIS and bicompartmental implant systems and costs associated with the accrual for employee bonus compensation plans. We expect our research and development expense to continue to increase as we continue to expand our research and development activities, including the development of version 2.0 of our TGS and our bicompartmental implant systems and research of potential future products.

Depreciation and Amortization. Depreciation and amortization expense was $483,000 for the three months ended September 30, 2008, compared to $344,000 for the three months ended September 30, 2007. The increase of $139,000, or 40%, was primarily due to an increase in depreciation of property and equipment as a result of purchases made during 2008 and 2007.

Interest and Other Income. Interest income was $241,000 for the three months ended September 30, 2008, compared to $308,000 for the three months ended September 30, 2007. The decrease of $67,000, or 22%, was primarily due to lower yields realized on our cash, cash equivalents and investments for the three months ended September 30, 2008 compared with the same period of 2007.

Interest and Other Expenses. Interest and other expenses were $0 for the three months ended September 30, 2008, compared to $77,000 for the three months ended September 30, 2007. Through February 2008, interest and other expense consisted primarily of the amortization of the $590,000 discount associated with a deferred payment to IBM of $4.0 million which had been fully amortized and paid upon the completion of our IPO in February 2008.

Income Taxes. No income taxes were recognized for the three months ended September 30, 2008 and 2007, due to net operating losses in each period. In addition, no current or deferred income taxes were recorded for the three months ended September 30, 2008 and 2007, as all income tax benefits were fully offset by a valuation allowance against our net deferred income tax assets.

Comparison of the Nine Months Ended September 30, 2008 to the Nine Months Ended September 30, 2007

Revenue. Revenue was $2.0 million for the nine months ended September 30, 2008, compared to $355,000 for the nine months ended September 30, 2007, and was primarily generated from the sale of implants and disposable products utilized in MAKOplasty procedures. The increase in revenue of $1.6 million was primarily due to an increase in MAKOplasty procedures performed during the nine months ended September 30, 2008. There were 401 procedures performed during the nine months ended September 30, 2008 compared to 71 procedures performed during the nine months ended September 30, 2007. The increase was also attributable to a $316,000 increase in other revenue, which consists primarily of service revenue on extended warranty services and net royalty revenues.

Table of Contents

Cost of Revenue. Cost of revenue was $2.2 million for the nine months ended September 30, 2008, compared to $291,000 for the nine months ended September 30, 2007. The increase in cost of revenue of $1.9 million was primarily due to an increase in MAKOplasty procedures performed, a $595,000 write-off of obsolete and discontinued inventory in 2008 primarily due to the launch of our RESTORIS implant system and the anticipated launch of version 2.0 of our TGS, the establishment of warranty accruals on sales of eight TGS units and royalties incurred on sales of eight TGS units during the nine months ended September 30, 2008.

Selling, General and Administrative. Selling, general and administrative expense was $16.0 million for the nine months ended September 30, 2008, compared to $7.7 million for the nine months ended September 30, 2007. The increase of $8.3 million, or 108%, was primarily due to an increase in sales, marketing and operations costs associated with the commercialization of our products and an increase in general and administrative costs to support growth and costs associated with operating as a public company. Selling, general and administrative expense for the nine months ended September 30, 2008 also included $1.4 million of stock-based compensation expense compared with $661,000 for the same period of 2007. The increase in stock-based compensation expense was primarily due to additional option and restricted stock grants made in 2008 and 2007.

Research and Development. Research and development expense was $9.2 million for the nine months ended September 30, 2008, compared to $5.3 million for the nine months ended September 30, 2007. The increase of $3.9 million, or 72%, was primarily due to an increase in research and development activities associated with on-going development of versions 1.2 and 2.0 of our TGS and the MAKO implant systems; and a nonrecurring charge of $949,000 associated with the vesting in full, upon completion of our IPO in February 2008, of restricted common stock issued pursuant to business consultation agreements entered into in December 2004.

Depreciation and Amortization. Depreciation and amortization expense was $1.3 million for the nine months ended September 30, 2008, compared to $915,000 for the nine months ended September 30, 2007. The increase of $415,000, or 45%, was primarily due to an increase in depreciation of property and equipment as a result of purchases made during 2008 and 2007.

Interest and Other Income. Interest income was $642,000 for the nine months ended September 30, 2008, compared to $860,000 for the nine months ended September 30, 2007. The decrease of $218,000, or 25%, was primarily due to lower yields realized on our cash, cash equivalents and investments for the nine months ended September 30, 2008 compared with the same period of 2007.

Interest and Other Expenses. Interest and other expenses were $110,000 for the nine months ended September 30, 2008, compared to $229,000 for the nine months ended September 30, 2007. Through February 2008, interest and other expense consisted primarily of the amortization of the $590,000 discount associated with a deferred payment to IBM of $4.0 million which had been fully amortized and paid upon the completion of our IPO in February 2008. Interest and other expense also included the write down of our variable auction rate securities in the first quarter of 2008 as discussed below under the caption, “Liquidity and Capital Resources,” and in Item 1, Financial Statements, Note 3, Short-Term Investments and Long-Term Investments .

Income Taxes. No income taxes were recognized for the nine months ended September 30, 2008 and 2007, due to net operating losses in each period. In addition, no current or deferred income taxes were recorded for the nine months ended September 30, 2008 and 2007, as all income tax benefits were fully offset by a valuation allowance against our net deferred income tax assets.

Liquidity and Capital Resources

(in thousands)	Nine Months Ended September 30,
	2008			2007
Cash used in operating activities	$	(21,702	)	$	(9,668	)
Cash used in investing activities		(3,587	)		(6,268	)
Cash provided by financing activities		46,489			27,879
Net increase in cash and cash equivalents	$	21,200		$	11,943

Table of Contents

We have incurred net losses and negative cash flow from operating activities for each period since our inception in November 2004. As of September 30, 2008, we had an accumulated deficit of $69.4 million and financed our operations principally through the sale of Series A, Series B and Series C redeemable convertible preferred stock and the completion of the IPO of our common stock. Through September 30, 2008, we received net proceeds of $52.2 million from the issuance of Series A, Series B and Series C redeemable convertible preferred stock. In February 2008, we completed our IPO of common stock, issuing a total of 5.1 million shares at an issue price of $10.00 per share, resulting in net proceeds to us, after expenses, of approximately $43.7 million. In conjunction with the closing of the IPO, in February 2008, all of our outstanding Series A, Series B and Series C redeemable convertible preferred stock was converted into 10,945,080 shares of common stock, as adjusted for a one-for-3.03 reverse stock split, which has been retroactively reflected in the accompanying condensed financial statements.

As of September 30, 2008, we had approximately $30.9 million in cash, cash equivalents and short-term investments. Our cash and short-term investment balances are held in a variety of interest bearing instruments, including certificates of deposit.

As of September 30, 2008, we held $1,025,000 par value of variable auction rate securities issued by two separate funds. In February 2008, the auction rate securities experienced failed auctions that limited the liquidity of these securities. Based on current market conditions, it is likely that auction failures will continue. Historically, the fair value of auction rate securities approximated par value due to the frequent resets through the auction rate process. The uncertainty in the credit markets affected our holdings in auction rate securities and the liquidity and fair value of these investments has been negatively impacted. An other-than-temporary impairment charge of $63,000 was recorded in the first quarter of 2008 to reduce the value of our auction rate securities to the new fair value. As of September 30, 2008, the auction rate securities were recorded at the estimated fair value of $987,000. In addition, as a result of the unresolved liquidity concerns, we reclassified our auction rate securities from short-term investments to long-term investments in 2008. Our investment firm has informed us that it intends to redeem our auction rate securities in early 2009 at par value. Based on current market conditions and the uncertainty of future conditions, however, we believe long-term classification remains appropriate. The carrying value of the securities are fully collateralized by assets held by the funds and were rated AAA prior to the failed auctions of the securities.

In October 2008, we entered into a Securities Purchase Agreement for an equity financing of up to $60 million, with initial gross proceeds of $40 million, which we closed on October 31, 2008, and conditional access to an additional $20 million called the Second Closing. In connection with the financing, we issued and sold to the participating investors 6,451,613 shares of our common stock at a purchase price of $6.20 per share and issued warrants to the participating investors to purchase 1,290,323 shares of common stock at an exercise price of $7.44 per share. The warrants will become exercisable in 180 days and have a seven-year term. Subject to the satisfaction of certain business related milestones before December 31, 2009, and approval of the Second Closing by our stockholders, we will have the right to require certain participants in the financing to purchase an additional $20 million of common stock and warrants to purchase common stock. At the initial closing, the investors that agreed to provide the additional $20 million investment received warrants to purchase an additional 322,581 shares of common stock at an exercise price of $6.20 per share. For more information regarding the equity financing, see Item 1, Financial Statements, Note 8 to the Condensed Financial Statements.

Net Cash Used in Operating Activities

Net cash used in operating activities primarily reflects the net loss for those periods, which was reduced in part by depreciation and amortization, stock-based compensation, inventory write-downs and accrued interest. Net cash used in operating activities was also affected by changes in operating assets and liabilities. Included in changes in operating assets for the nine months ended September 30, 2008 are approximately $5.5 million of increases to the deferred revenue balance compared to $1.3 million for the nine months ended September 30, 2007. This was partially offset by approximately $2.0 million and $354,000 of increases to the deferred cost of revenue balance for the nine months ended September 30, 2008 and 2007, respectively. The increases to the deferred revenue and deferred cost of revenue balances are primarily related to unit sales of our TGS during the period. Deferred revenue and deferred cost of revenue related to unit sales of our TGS will be recognized in the statements of operations upon satisfaction of all related revenue recognition criteria.

Table of Contents

Net Cash Used in Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2008 is primarily attributable to the payment of the $4.0 million deferred license fee due to IBM upon completion of our IPO, as discussed under the caption “Contractual Obligations,” to purchases of $1.6 million of property and equipment as we invest in the infrastructure of our growing company and to $2.0 million of purchases of investments, which was partially offset by proceeds of $4.0 million from sales and maturities of investments. Net cash used in investing activities for the nine months ended September 30, 2007 is primarily attributable to the purchases and proceeds of investments as we manage our investment portfolio to provide interest income and liquidity, purchases of $1.2 million of property and equipment and $450,000 for the acquisition of intangible assets.

Net Cash Provided by Financing Activities

Net cash provided by our financing activities for the nine months ended September 30, 2008 and 2007 was primarily attributable to net proceeds received in connection with our IPO in February 2008 and the issuance of Series C redeemable convertible preferred stock in February 2007, respectively.

Operating Capital and Capital Expenditure Requirements

To date, we have not achieved profitability. We anticipate that we will continue to incur substantial net losses for at least the next several years as we expand our sales and marketing capabilities in the orthopedic products market, develop and commercialize version 2.0 of our TGS and our bicompartmental implant system and continue to develop the corporate infrastructure required to sell and market our products and operate as a public company. We also expect to experience increased cash requirements for inventory and property and equipment in conjunction with the anticipated commercial launch of version 2.0 of our TGS and bicompartmental implant system in the first half of 2009, subject to regulatory clearances or approvals.

We believe our existing cash, cash equivalents and short-term investment balances, together with the net proceeds of the financing transaction as discussed Item 1, Financial Statements, Note 8 to Condensed Financial Statements, and interest income we earn on these balances will be sufficient to meet our anticipated cash requirements for at least the next 12 months. To the extent our available cash, cash equivalents and short-term investment balances are insufficient to satisfy our operating requirements after that period, we will need to seek additional sources of funds, including selling additional equity or debt securities or entering into a credit facility. The sale of additional equity and debt securities may result in dilution to our current stockholders. If we raise additional funds through the issuance of debt securities, these securities may have rights senior to those of our common stock and could contain covenants that could restrict our operations. We may require additional capital beyond our currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, or at all. If we are unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned research, development and commercialization activities, which could materially harm our business and results of operations.

We are in the process of developing version 2.0 of our TGS. If completion of version 2.0 of our TGS unit is unsuccessful or delayed, or regulatory clearances or approvals are denied or delayed, it could have a material adverse impact on our results of operations and financial position and we may be unable to recognize any revenue associated with sales of our TGS. No right of return exists on sales of prior versions of our TGS if we are unable to complete and deliver version 2.0 of our TGS as anticipated.

Because of the numerous risks and uncertainties associated with the development of medical devices, such as version 2.0 of our TGS and bicompartmental implant system, we are unable to estimate the exact amounts of capital outlays and operating expenditures necessary to complete the development of the products and successfully deliver commercial products to the market. Our future capital requirements will depend on many factors, including but not limited to the following:

Table of Contents

•

the revenue generated by sales of our current and future products;

•

the expenses we incur in selling and marketing our products;

•

the costs and timing of regulatory clearance or approvals for upgrades or changes to our products;

•

the rate of progress and cost of on-going development activities;

•

the success of our on-going research and development efforts;

•

the emergence of competing or complementary technological developments;

•

the costs of filing, prosecuting, defending and enforcing any patent or license claims and other intellectual property rights, or participating in litigation-related activities;

•

the terms and timing of any collaborative, licensing, or other arrangements that we may establish; and

•

the acquisition of businesses, products and technologies, although we currently have no understandings, commitments or agreements relating to any material transaction of this type.

Contractual Obligations

In March 2006, we entered into a license agreement with IBM in exchange for a payment of $2.0 million upon execution of the agreement and a payment of $4.0 million in the form of a deferred license fee to IBM upon, among other things, the closing of the IPO of our common stock. In February 2008, upon closing of our IPO, the Company paid the $4.0 million deferred license fee due to IBM.

At September 30, 2008, we were committed to make future purchases for inventory related items under various purchase arrangements with fixed purchase provisions aggregating approximately $5.7 million.

Other than as described above and scheduled payments through September 30, 2008, there have been no significant changes in our contractual obligations during the nine months ended September 30, 2008 as compared to the contractual obligations described in our Form 10-K.

Recent Accounting Pronouncements

Effective January 1, 2008, we adopted SFAS No. 157, Fair Value Measurements , or SFAS 157. SFAS 157 defines fair value, provides a consistent framework for measuring fair value under accounting principles generally accepted in the United States and expands fair value financial statement disclosure requirements. SFAS 157 does not require any new fair value measurements. It only applies to accounting pronouncements that already require or permit fair value measures, except for standards that relate to share-based payments.

•

Level 1 Inputs– Quoted prices for identical instruments in active markets.

•

Level 2 Inputs– Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

•

Level 3 Inputs– Instruments with primarily unobservable value drivers.

The adoption of SFAS 157 did not have a material impact on our results of operations and financial condition.

Table of Contents

Effective January 1, 2008, we adopted SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115, or SFAS 159, and have not elected to use fair value measurement on any assets or liabilities under this statement. We have determined that the adoption of SFAS 159 had no effect on our results of operations and financial position.

Effective January 1, 2008, we adopted EITF Issue No. 07-03, Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities , or EITF 07-03. EITF 07-03 requires that nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. Such amounts should be recognized as an expense as the related goods are delivered or the related services are performed. Entities should continue to evaluate whether they expect the goods to be delivered or services to be rendered. If an entity does not expect the goods to be delivered or services to be rendered, the capitalized advance payment should be charged to expense. We have determined that the adoption of EITF 07-03 had no effect on our results of operations and financial position.

In June 2008, the EITF issued Issue No. 07-05, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock (“EITF 07-05”). EITF 07-05 addresses the determination of whether an instrument (or an embedded feature) is indexed to an entity’s own stock, if an instrument (or an embedded feature) that has the characteristics of a derivative instrument is indexed to an entity’s own stock, it is still necessary to evaluate whether it is classified in stockholders’ equity (or would be classified in stockholders’ equity if it were a freestanding instrument). In addition, for some instruments that are potentially subject to the guidance in EITF Issue No. 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock , but do not have all the characteristics of a derivative instrument under paragraphs 6 through 9, it is still necessary to evaluate whether it is classified in stockholders’ equity. It is effective for financial statements issued for fiscal years beginning after December 15, 2008. We are currently evaluating the impact that EITF 07-05 will have on its financial statements.

Other than as described above, there have been no significant changes in Recent Accounting Pronouncements during the nine months ended September 30, 2008 as compared to the Recent Accounting Pronouncements described in our Form 10-K.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Our exposure to market risk is confined to our cash, cash equivalents and short-term investments that have maturities or interest reset dates of less than one year. The goals of our cash investment policy are the security of the principal invested and fulfillment of liquidity needs, with the need to maximize value being an important consideration. To achieve our goals, we maintain a portfolio of cash equivalents and investments in a variety of securities. The securities in our investment portfolio are not leveraged, are classified as available for sale and are generally short-term in nature. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that a variation in market rates would have any material impact on the value of our investment portfolio.

Table of Contents

Item 4T. CONTROLS AND PROCEDURES.

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934, or the Exchange Act, our management evaluated, with the participation of our chief executive officer and chief financial officer, or the Certifying Officers, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of September 30, 2008. Based upon their evaluation of these disclosure controls and procedures, our Certifying Officers concluded that the disclosure controls and procedures were effective as of September 30, 2008 to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the SEC rules and forms, and to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

We believe that a controls system, no matter how well designed and operated, is based in part upon certain assumptions about the likelihood of future events, and therefore can only provide reasonable, not absolute, assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Table of Contents

PART II

OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS.

The information with respect to SensAble Technologies, Inc. set forth in Part I, Item 1, Financial Statements, Note 5, Commitments and Contingencies , of this report is incorporated into this item by this reference.

Item 1A. RISK FACTORS .

There have been no material changes in our risk factors from those disclosed in our Form 10-K.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Our IPO was effected through a registration statement on Form S-1 (File No. 333-146162) that was declared effective by the SEC on February 14, 2008. We registered 5,100,000 shares of our common stock with an aggregate offering price of $51 million, all of which shares we sold. The offering was completed after the sale of all 5,100,000 shares. J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated were the joint book-running managing underwriters of the IPO and Cowen and Company and Wachovia Securities acted as co-managers. The underwriters elected not to exercise their over-allotment option. We paid $3.6 million of the proceeds in underwriting discounts and commissions and incurred an additional $3.7 million of expenses. None of the expenses were paid, directly or indirectly, to directors, officers or persons owning 10% or more of our common stock, or to our affiliates.

We currently intend to use the proceeds from the IPO, net of the payment of the $4.0 million IBM deferred license fee and the underwriting discounts and commissions, as set forth below. See Part I, Item 1, Financial Statements, Note 5, Commitments and Contingencies , and Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of this report for more information regarding payment of the IBM license fee.

•

Approximately $14.0 - $20.0 million for the expansion of sales and marketing activities;

•

Approximately $12.0 - $18.0 million for continuation of research and development activities; and

•

The remainder to fund working capital and other general corporate purposes, including the expenses associated with the IPO.

Management has broad discretion over the uses of the proceeds of the IPO. Except for payment of the IBM deferred license fee, we did not use any material amount of the IPO proceeds during the three months ended March 31, 2008. Since April 1, 2008, we have used approximately $5.5 million of the proceeds for sales and marketing activities, $5.6 million for research and development activities and $4.0 million for working capital and general corporate purposes. The remainder of the IPO proceeds is invested in highly liquid, short-term, interest-bearing funds.

Table of Contents

Item 6. EXHIBITS.

Exhibit

No.

Description

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act

31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act

32.1	Certification of Chief Executive Officer pursuant to18 U.S.C. §1350

32.2	Certification of Chief Financial Officer pursuant to18 U.S.C. §1350

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MAKO Surgical Corp.
Date: November 7, 2008	By:	/s/ Fritz L. LaPorte
		Fritz L. LaPorte Senior Vice President of Finance and Administration, Chief Financial Officer and Treasurer

Table of Contents

EXHIBIT INDEX

Exhibit

No.

Description

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act

31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act

32.1	Certification of Chief Executive Officer pursuant to18 U.S.C. §1350

32.2	Certification of Chief Financial Officer pursuant to18 U.S.C. §1350

Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Mako Surgical Corp. (MM) Charts.

Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jul 2023 to Jul 2024

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

MAKO Mako Surgical Corp. (MM)

Latest MAKO Messages

Loading Messages....

News

Loading Messages....

Your Recent History